Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.70 |
| ▸ | RET | P07949 | 14/20 | 0.64 |
| ▸ | KIF5B | P33176 | 13/20 | 0.64 |
| ▸ | KDR | P35968 | 13/20 | 0.64 |
| ▸ | RAF1 | P04049 | 1/20 | 0.59 |
| ▸ | BRAF | P15056 | 1/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.58 |
| ▸ | FLT1 | P17948 | 2/20 | 0.58 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.58 |
| ▸ | FLT4 | P35916 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30459542 | 0.91 | EGFR (0.70) | EGFRRETKIF5BKDRRAF1 | |
| SCHEMBL29453257 | 0.91 | EGFR (0.70) | EGFRRETKIF5BKDRRAF1 | |
| SCHEMBL14843536 | 0.91 | EGFR (0.70) | EGFRRETKIF5BKDRRAF1 | |
| Hydrochloric Acid SCHEMBL28257165 | 0.90 | EGFR (0.69) | EGFRRETKIF5BKDRRAF1 | |
| SCHEMBL202827 | 0.87 | EGFR (0.73) | EGFRRETKIF5BKDRFLT1 | |
| SCHEMBL29781309 | 0.87 | EGFR (0.73) | EGFRRETKIF5BKDRFLT1 | |
| SCHEMBL6018368 | 0.87 | EGFR (0.68) | EGFRRETKIF5BKDRFGFR1 | |
| SCHEMBL17179538 | 0.87 | EGFR (0.70) | EGFRRETKIF5BKDRRAF1 | |
| Hydrochloric Acid SCHEMBL907165 | 0.86 | EGFR (0.67) | EGFRRETKIF5BKDRFGFR1 | |
| Methane SCHEMBL5123634 | 0.86 | EGFR (0.72) | EGFRRETKIF5BKDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859767-B2 | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used therein | HANMI SCIENCE CO., LTD (KR) | 2014-10-14 | — | — | US | disclosed |
| US-20140275534-A1 | METHOD FOR PREPARING 1-(4-(4-(3,4-DICHLORO-2-FLUOROPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY) PIPERIDIN-1-YL)-PROP-2-EN-1-ONE HYDROCHLORIDE AND INTERMEDIATES USED THEREIN | HANMI SCIENCE CO., LTD. (KR) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275534-A1 | METHOD FOR PREPARING 1-(4-(4-(3,4-DICHLORO-2-FLUOROPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY) PIPERIDIN-1-YL)-PROP-2-EN-1-ONE HYDROCHLORIDE AND INTERMEDIATES USED THEREIN | EGFR, ERBB2, ERBB3 | EGFR 1/4885RET 9/4885KIF5B 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.